OSCIENCES Tra n sfo r m i n g D i s e a s e M a n a g e m e nt A u g u s t 8 , 2 0 2 2 D i s c l a i m e rs 2 F O R W A R D - L O O K I N G S T A T E M E N T S This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of IR & Corporate Communications Derek Maetzold - Founder, President & CEO Frank Stokes - CFO Conference Call Participants Mason Carrico - Stephens Tom Peterson - Baird Puneet Souda - SVB Leerink Operator Good afternoon, and welcome to the Castle Biosciences Second Quarter 2022 Conference Call. As a reminder, today’s call is being recorded. We will begin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Dela ...

Tra n sfo rmi n g D i s e as e M a n age me nt M a y 9 , 2 0 2 2 D i s c l a i m e r s 2 F O R W A R D - L O O K I N G S T A T E M E N T S This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: estimated sizes of ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2022 Results Conference Call May 9, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of Investor Relations and Corporate Communications Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Catherine Schulte - Baird Mason Carrico - Stephens Thomas Flaten - Lake Street Capital Markets Kyle Mikson - Canaccord Mark Massaro - BTIG Operator Go ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Del ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Camilla Zuckero - Executive Director of Investor Relations and Corporate Communications Derek Maetzold - Founder, President and Chief Executive Officer Frank Stokes - Chief Financial Officer Conference Call Participants Catherine Schulte - Baird Puneet Souda - SVB Leerink Kyle Mikson - Canaccord Thomas Flaten - Lake Street Capital Disclaimer*: This transcript is designed to be used along ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2021 Earnings Conference Call November 8, 2021 4:30 PM ET Company Participants Camilla Zuckero - Executive Director, IR & Corporate Communications Derek Maetzold - Founder, President & CEO Frank Stokes - CFO Conference Call Participants Sung Ji Nam - BTIG Kyle Mikson - Canaccord Thomas Flaten - Lake Street Capital Markets Catherine Schulte - R.W. Baird Puneet Souda - SVB Leerink Paul Knight - KeyBanc Operator Good afternoon and welcome to Castle Biosciences Third Qu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 Delaware 77-0701774 (State or other jurisdiction of incorporation or organizati ...